Modular engineered outer membrane vesicles for synergistic cancer immunotherapy via PD-L1 blockade and epigenetic reprogramming
Immune checkpoint inhibitors have significantly improved therapeutic outcomes in advanced melanoma; however, their clinical efficacy is greatly limited by low overall response rates and the primary or acquired resistance. Here, we developed a SpyCatche…